Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of remazolam with sufentanil on bispectral index during general anesthesia induction
ChiCTR2200067040Phase 4Not yet recruiting
- Sponsor
- The Second People’s Hospital of Foshan
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of remimazolam mesylate in None (4 arms), sponsored by The Second People’s Hospital of Foshan. Primary endpoint: bispectral index. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
remimazolam mesylate
Beyond the preview
Go deeper on ChiCTR2200067040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067040.